KROS
Keros·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Stock Price Surged Significantly
Ample Liquidity
High Gross Profit Margin
RSI Overbought
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About KROS
Keros Therapeutics, Inc.
A clinical-stage biopharmaceutical company that developing products for hematological and musculoskeletal disorders
1050 Waltham Street, Suite 302 02421, Lexington, Massachusetts
--
Keros Therapeutics, Inc., was originally incorporated under the laws of the State of Delaware in December 2015. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for patients with hematological and musculoskeletal diseases. The company is a leader in understanding the role of transforming growth factor-beta (a family of proteins), a major regulator of red blood cell and platelet production and muscle and bone growth, repair and maintenance.
Company Financials
EPS
KROS has released its 2025 Q3 earnings. EPS was reported at -0.18, versus the expected -0.92, beating expectations. The chart below visualizes how KROS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
KROS has released its 2025 Q3 earnings report, with revenue of 14.26M, reflecting a YoY change of 3575.77%, and net profit of -7.28M, showing a YoY change of 86.25%. The Sankey diagram below clearly presents KROS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
